Maintenance Venetoclax Based Therapy Post Complete Remission In AML Fit Patients

Maintenance Venetoclax Based Therapy Post Complete Remission In AML Fit Patients - VEN-MAIN

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500111062

Enrollment

Unknown

Registered

2025-10-24

Start date

2025-11-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia

Interventions

venetoclax group:Patients will receive Venetoclax maintenance therapy after achieving complete remission. Venetoclax will be administered orally at the standard maintenance dose (e.g., 400 mg once dai

placebo group:Patients Will receive Best supportive care with follow up

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1-Age : 18 - 60 years . 2-Patients who are not eligible for immediate bone marrow transplantation. 3-Newly diagnosed AML patients who attained CR after 1st line. 4-Refractory / recurrant AML patients .

Exclusion criteria

Exclusion criteria: 1-Patients not on CR . 2-Age : younger than 18 or older than 60 3-Patients not eligible for bone marrow transplation

Design outcomes

Primary

Measure	Time frame
disease free survival ;	—

Secondary

Measure	Time frame
overall survival ;quality of life and side effect;	—

Countries

Egypt

Contacts

Public Contactprof. Elsayed Mostafa Ali

Sohag university

www.ibrahimeman577@gmail.com+20 10 01638744

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026